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Background: Specific mutations of the epidermal growth factor
receptor (EGFR) gene are predictive for favorable response to
tyrosine kinase inhibitors (TKIs) and are associated with a good
prognosis. In contrast, Kirsten rat sarcoma viral oncogene homolog
(KRAS) mutation has been shown to predict poor response to such
therapy. Nevertheless, tumor that initially responds to EGFR-TKIs
almost inevitably becomes resistant later. Other mechanisms of
resistance to EGFR inhibitors could involve activating mutations of
the other main EGFR effector pathway, i.e., the phosphoinositide-
3-kinase/phosphate and tensin homologue deleted from chromo-
some 10 (PTEN)/alpha serine/threonine protein kinase (AKT) path-
way. The aim of this study was to investigate the role of
phosphoinositide-3-kinase catalytic alpha (PIK3CA), EGFR, and
KRAS gene mutations in predicting response and survival in patients
with non-small cell lung cancer (NSCLC) treated with EGFR-TKIs.
Patients and Methods: A total of 166 patients with advanced
NSCLC treated with EGFR-TKI with available archival tissue
specimens were included. PIK3CA, EGFR, and KRAS mutations
were analyzed using polymerase chain reaction-based sequencing.
Results: EGFR mutation was detected in 25.3% of patients,
PIK3CA mutation in 4.1%, and KRAS mutation in 6.7%. PIK3CA
mutation correlated with shorter median time to progression (TTP)
(p  0.01) and worse overall survival (OS) (p  0.001). EGFR
mutation (p  0.0001) correlated with favorable response to TKIs
treatment and longer TTP (p  0.0001). KRAS mutation correlated
with progressive disease (p  0.05) and shorter median TTP (p 
0.003) but not with OS. Cox multivariate analysis including histology
and performance status showed that PIK3CAmutation was an indepen-
dent factor to predict worse OS (p  0.0001) and shorter TTP (p 
0.03), while KRAS mutation to predict shorter TTP (p  0.01).
Conclusion: PIK3CA and KRAS mutations seem to be indicators of
resistance and poor survival in patients with NSCLC treated with
EGFR-TKIs.
Key Words: PI3KCA, EGFR, KRAS mutations, Response to EGFR
TKIs, Survival, NSCLC.
(J Thorac Oncol. 2011;6: 707–715)
Recently, novel molecular-targeted strategies that blockcancer progression pathways have been evaluated as a
new therapeutic approach for treating non-small cell lung
cancer (NSCLC).1
Epidermal growth factor receptor (EGFR) overexpres-
sion is observed in tumors of more than 60% of patients with
metastatic NSCLC, and it is correlated with poor prognosis.2
These findings have provided a rationale for the devel-
opment of novel anticancer agents that target EGFR. Ge-
fitinib (Iressa: AstraZeneca Macclesfield, United Kingdom)
and erlotinib (Tarceva; OSI Pharmaceuticals Inc., Melville,
NY), small-molecule tyrosine kinase inhibitors (TKIs), have
been designed to act as competitive inhibitors of adenosine
triphosphate binding at the active site of EGFR kinase.
Both targeted therapeutic agents produce responses, in
phase II to phase III trials, in approximately 10% of European
patients and in 20% of patients from East Asian that had
progressed with prior chemotherapy.2–7 Specific mutations in
the tyrosine kinase domain (exons 18–21) of the EGFR gene
are predictive for favorable response to TKIs and are associ-
ated with a good prognosis such as other prognostic features
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including Asian ethnicity, female gender, and never smokers
status.8–10 In contrast, Kirsten rat sarcoma viral oncogene
homolog (KRAS) gene mutation, which occurs in 20 to 30%
of NSCLCs, mainly in adenocarcinomas (ADCs, 30%) and
smokers, seems to confer resistance to EGFR targeting
agents, and it is reported to be mutually exclusive with EGFR
or HER2 gene mutations.11–14 KRAS is a downstream medi-
ator of EGFR-induced cell signaling, and ras mutations con-
fer constitutive activation of the signaling pathways without
EGFR activation. Several retrospective studies showed pro-
longed survival in gefitinib-treated patients with tyrosine
kinase activating mutations.8,9,15–18
Other mechanisms of resistance to EGFR inhibitors
could involve activating mutations of the other main EGFR
effector pathway, i.e., the phosphoinositide-3-kinase (PI3K)/
PTEN/AKT pathway.
PI3K is an activator of serine/threonine kinase Akt,
which regulates cell tumoral survival, apoptosis, prolifera-
tion, motility, growth, and cytoskeletal rearrangement. Akt
has been shown to be frequently activated in NSCLC, sug-
gesting that the PI3K/AKT pathway plays an important role
in the oncogenesis and progression of human lung cancers,
and some of these functional derangements could be candi-
date targets for cancer therapy.
It is well established that PI3K is activated by stimulation
of receptor tyrosine kinases. Recently, in addition to this mech-
anism, somatic mutations of phosphoinositide-3-kinase catalytic
alpha (PIK3CA) gene have been shown to play an important role
in the activation of PI3K and of Akt signaling pathway.10
Although mutations were relatively common in colorectal can-
cer (32%), breast cancer (26–40%), hepatocellular carcinoma
(35%), and some ovarian cancers (20%), it is rare in NSCLC
(1–4%).19,20 A great majority of somatic mutations in PIK3CA
are missense mutations clustering in exons 9 and 20 that encode
a part of the helical and kinase domains, respectively. Mutant
PIK3CA stimulates the Akt pathway and promotes cell growth
in several cancers, including colon cancer, and it has been
associated with poor prognosis.20 In advanced NSCLC, little
data exist on PIK3CA mutations,21,22 and their clinical signifi-
cance in terms of TKIs responsiveness and outcome has not
elucidated. Therefore, to further identify TKIs sensitivity and
resistance mechanisms, we have investigated PIK3CA, EGFR,
and KRAS gene mutations in patients with advanced NSCLC
who had been treated with gefitinib or erlotinib after failure of
previous chemotherapy, and we correlated the results of
PIK3CA, EGFR, and KRAS gene mutations with response to
TKIs and outcome.
MATERIALS AND METHODS
Patients Selection
This retrospective study was conducted in a cohort of
240 patients with NSCLC followed up at the Medical Oncol-
ogy Department, S. Maria della Misericordia Hospital in
TABLE 1. Primers Used in EGFR, PIK3CA, and KRAS Mutation Analysis
Gene Sense (5-3) Antisense (5-3)
EGFR exon 18
External ATGGTGAGGGCTGAGGTGAC TCCCCACCAGACCATGAGAG
Internal GACCCTTGTCTCTGTGTTCTTGT CCAGACCATGAGAGGCCCTG
EGFR exon 19
External GCAATATCAGCCTTAGGTGCGGCTC CATAGAAAGTGAACATTTAGGATGTG
Internal CCTTAGGTGCGGCTCCACAGC CATTTAGGATGTGGAGATGAGC
EGFR exon 20
External CCATGAGTACGTATTTTGAAACTC CATATCCCCATGGCAAACTCTTGC
Internal GAAACTCAAGATCGCATTCATGC GCAAACTCTTGCTATCCCAGGAG
EGFR exon 21
External CTAACGTTCGCCAGCCATAAGTCC GCTGCGAGCTCACCCAGAATGTCTGG
Internal CAGCCATAAGTCCTCGACGTGG CATCCTCCCCTGCATGTGTTAAAC
PIK3CA exon 9
External TCTGTAAATCATCTGTGAAT AATTCTGCTTTATTTATTCC
Internal ATCATCTGTGAATCCAGAGG TTTTAGCACTTACCTGTGAC
PIK3CA exon 20
External AACATCATTTGCTCCAAACT TGTGGAATCCAGAGTGAGCT
Internal GCTCCAAACTGACCAAACTG ATCCAGAGTGAGCTTTCATT
KRAS exon 2
External GTTCTAATATAGTCACATTT ACTCATGAAAATGGTCAGAGAAACCTTTAT
Internal AGTCACATTTTCATTATTTT AGAAACCTTTATCTGTATCAAAGAATG
KRAS exon 3
External GAAGTAAAAGGTGCACTGTA AACTATAATTACTCCTTAAT
Internal GTGCACTGTAATAATCCAGA ACTCCTTAATGTCAGCTTAT
M13 TGTAAAACGACGGCCAGT CAGGAAACAGCTATGACC
EGFR, epidermal growth factor receptor; PIK3CA, phosphoinositide-3-kinase catalytic alpha; KRAS, Kirsten rat sarcoma viral oncogene
homolog.
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Perugia (Italy) who had been treated with gefitinib or erlo-
tinib after failure of platinum-based chemotherapy.
In this study, we evaluated response to TKIs, time to
progression (TTP), and survival according to the presence of
EGFR, PIK3CA, and KRASmutations. Patients were included
into the analysis if they had histologically confirmed diagno-
sis of NSCLC with locally advanced (stage III) or metastatic
disease, progressing or relapsing after chemotherapy or with
medical contraindications for chemotherapy; availability of
tumor tissue and full clinical data; and presence of at least one
measurable lesion according to the RECIST criteria.23 Treat-
ment consisted of 250 mg of gefitinib or 150 mg of erlotinib
administered orally once daily and continued until disease
progression, intolerable toxicity, or patient refusal. Tumor
response was assessed by computed tomography scan after 2
months, with a confirmatory evaluation to be repeated in
responders and in patients with stable disease at least 4 weeks
after the initial determination of response. Time to disease
progression was calculated from the date of initiation of TKIs
treatment to the date of detection of progressive disease or to
the date of the last contact. Survival was calculated from the
date of therapy initiation to the date of death or to the date of
the last contact. Survival status was collected until the end of
December 2009. Median duration of follow-up was 24.81
months (range, 4.90–117.96 months).
Patients were classified as never smokers (100 ciga-
rettes/lifetime), current smokers (with an average tobacco
consumption estimated at 43 pack-years; range, 20–100), or
former smokers (tobacco consumption stopped from 7.6 
4.2 years) with a previous average tobacco consumption
estimated at 47 pack-years (range, 20–106). Patients had
performance status ranging from grades 0 to 2. Performance
status was defined according to Eastern Cooperative Oncol-
ogy Group.24
The study was approved by the local Ethics Committee
and was conducted in accordance with ethical principles
stated in the most recent version of the Declaration of
Helsinki. Written informed consent for study biomarker anal-
yses was obtained from each patient entering the study.
DNA Sequencing
Formalin-fixed paraffin-embedded tissues obtained be-
fore any cancer therapy were obtained from the archives of
the Institute of Pathological Anatomy and Histology, Univer-
sity of Perugia. Histopathological classification was deter-
mined on hematoxylin-eosin–stained sections based on the
World Health Organization criteria.25
Formalin-fixed paraffin-embedded tumor blocks were
reviewed for quality and tumor content. Tumor cells (at least
70%) were macrodissected, and genomic DNA was isolated
using QIAmp DNA extraction kit and automatically purified
by BioRobot EZ1 instrument (Qiagen S.p.A., Milan, Italy)
according to the manufacturer’s instructions. Nested poly-
merase chain reactions (PCRs) were carried out using primers
listed in Table 1, to amplify exons 18 to 21 of EGFR, exons
9 and 20 of PIK3CA, and exons 2 to 3 of KRAS, as described
previously.26 To facilitate sequencing, internal primers incor-
porated an M13Tag. PCR products were purified with Exo-
nuclease 1 and Shrimp Alkaline Phosphatase (ExoSAP-IT) at
37°C for 15 minutes followed by heating at 80°C for 15
minutes to stop the enzymatic reaction. After purification, the
PCR products were sequenced with forward and reverse M13
primers and Big Dye Terminator v1.1 Cycle Sequencing Kit.
Sequencing fragments were detected by capillary electropho-
resis using 3500 Genetic Analyzer (Applied Biosystems,
Foster City, CA). Electropherograms were analyzed for the
presence of mutations using SeqScape v2.7 Software. In all
cases, samples harboring mutations were reamplified and
resequenced using the same experimental conditions.
Statistical Analysis
The statistical analyses of categorical variables were
done using the Pearson’s 2 test or the Fisher’s exact test
where appropriate. Kaplan-Meier estimates of survival curves
were computed for TTP and overall survival (OS). Log-rank
tests were used to compare the survival curves between
different subsets of patients. The response to TKI, as a
TABLE 2. Clinical and Demographic Characteristics of the
Patient Population
Characteristics
No. of
Cases Percentage
All patient 166 100
Median age, yr (range) 60.2 (25.6–84)
Sex
Male 91 54.8
Female 75 45.2
Stage
III 25 15.1
IV 141 84.9
Histology
ADC 102 61.5
BAC 17 10.2
SCC 28 16.9
LCC 6 3.6
Mixeda 7 4.2
Not otherwise specified NSCLC 6 3.6
Smoking history
Never smokers 61 36.8
Former smokers 47 28.3
Current smokers 46 27.7
Unknown 12 7.2
Therapy
Total patients treated with
EGFR-TKI therapy
166 100
Patients treated with Gefitinib 75 45.2
Patients treated with Erlotinib 91 54.8
Total patients treated with
previous chemotherapy
142/166 85.5
Patients treated with platinum-
based chemotherapy
125 75.3
Patients treated with
nonplatinum compounds
17 10.2
a Six patients had adenosquamous carcinoma, and one patient had large cell neuroen-
docrine carcinoma (50%), adenocarcinoma 30%, and squamous cell carcinoma 20%.
ADC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; SCC, squamous cell
carcinoma; LCC, large cell carcinoma; EGFR-TKI, epidermal growth factor receptor-
tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer.
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dependent variable, with clinical and molecular factors was
also investigated by logistic regression analysis to account for
the effect of the different variables. Multivariate analyses
were done using a logistic regression model for response to
TKIs and stepwise Cox regression models for TTP and OS to
identify independent biomarkers and to adjust for baseline
characteristics. All statistical tests were two sided, and sta-
tistical significance defined as p less than 0.05 was considered
significant. All analyses were performed using Matlab soft-
ware (The MathWorks ver. 7.2.0.232).
RESULTS
Patient Characteristics
Complete clinical information and tissue blocks for
molecular analysis were available from 166 of 240 patients
with advanced NSCLC. All the patients were whites, and
clinical and demographic characteristics are presented in
Table 2. Median age was 60.2 years (range, 25.6–84 years),
and the majority of patients were men (54.8%) in good
performance status (0–1, 95.8%). ADC was the most fre-
quent histology (61.4%), followed by squamous cell carci-
noma (16.9%), bronchioloalveolar carcinoma (BAC, 10.2%),
large cell carcinoma (3.6%), mixed histology (4.2%), and not
otherwise specified NSCLC (3.6%); most of the patients were
former and current smokers (56.0%).
Seventy-five (45.2%) patients were treated with ge-
fitinib and 91 (54.8%) patients with erlotinib during the study
period. Twenty-four patients received EGFR-TKIs therapy as
treatment of first line, 99 of second line, and 43 of third line.
Standard platinum-based doublets, as treatment of first
line, were offered to 125 of 142 (75.3%) patients. Seventeen
(10.2%) patients received single-agent chemotherapy with
gemcitabine or vinorelbine because of age (13 patients) or
due to the presence of comorbidity contraindicating platinum-
based chemotherapy (four cases).
Mutations of EGFR, PIK3CA, and KRAS Genes
Of 166 patients evaluated, EGFR mutations were found
in 42 of them (25.3%): two point mutations in exon 18
(G719A and G719S), 28 deletions in exon 19, two point
mutations in exon 20 (R776C and S784F), two insertion/
duplication in exon 20 (768insNPH and 766insMAS), and
eight point mutations in exon 21 (L858R). In three patients,
there was a second mutation (E709A_G719S, E709A_
G719A, and S784F_V786M). PIK3CA mutations were eval-
uated in 145 patients due to yielded insufficient DNA for
mutation testing and were mutated in six patients (4.1%): two
FIGURE 1. Mutations in the epidermal growth factor receptor (EGFR), KRAS, and phosphoinositide-3-kinase catalytic alpha
(PIK3CA) genes. Panel A, the nucleotide sequence of the EGFR gene in tumor specimens with heterozygous in-frame deletion
(delK745-A750) in exon 19 (double peaks). Tracing in both sense and antisense directions is shown to demonstrate the two
breakpoints of the deletion; the wild-type nucleotide sequence is shown in capital letters, and the mutant sequence is in low-
ercase letters. Panel B, the heterozygous mutation of EGFR in exon 21: a T to G base-pair change (arrow), resulting in a substi-
tution of leucine for arginine at position 858. Panel C, the heterozygous mutation of PIK3CA in exons 9 and 20: a G to A base-
pair change (arrow), resulting in a substitution of glutamic acid for lysine at position 545, a G to A base-pair change (arrow),
resulting in a substitution of methionine for isoleucine at position 1043. Panel D, the heterozygous mutation of KRAS in exon
2: a G to T base-pair change (arrow), resulting in a substitution of glycine for cysteine at position 12.
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point mutations in exon 9 (E542K and E545K) and four point
mutations in exon 20 (two M1043I, and one H1047Y,
G1049S, and each). One patient with PIK3CA mutation in
exon 20 (M1043I) had ADCs harboring an EGFR mutation
(deletions in exon 19). KRAS mutations at codons 12, 13, and
61 were evaluated in 162 patients and were found in 11
(6.7%) patients (two G12C, G12V, G12D, G12R, and Q61H
and one G12A). As reported of other authors, EGFR muta-
tions and KRAS mutations were mutually exclusive.15 Some
sequence chromatograms of EGFR, PIK3CA, and KRAS gene
mutations are shown in Figure 1.
Correlation of EGFR, PIK3CA, and KRAS
Mutations with Patients’ Clinical and
Pathologic Features
Clinical and pathologic characteristics and their corre-
lation with genetic abnormalities are presented in Table 3.
EGFR mutations were significantly more frequent in ADC/
BAC/mixed histology (30.2% versus 10.0%. p  0.01). The
associations with sex and smoking status were not statisti-
cally significant (p  0.10 and p  0.10, respectively),
although EGFR mutations were more frequent in women and
in nonsmokers. No significant associations of PIK3CA and
KRAS mutations were detected with the clinical and patho-
logical features. No difference was found according to inhib-
itor administered (gefitinib or erlotinib) and the presence or
absence of EGFR mutations.
Response to EGFR-TKIs According to Clinical
and Molecular Parameters
For the entire group, the objective response rate to
EGFR-TKIs was 33.1% (13 complete and 42 partial re-
sponses), disease control rate (complete response  partial
response  stable disease) was 57.2%, the median TTP was
8.9 months, the median survival was 31.9 months, and 1-year
survival was 78.3%. As summarized in Table 4, never-
smoking status (45.9% versus 26.7%, p  0.02) and ADC/
BAC/mixed histology (38.1% versus 17.5%, p  0.02) were
significantly statistically associated with better response. The
patients with performance status 0 had a trend toward a
higher probability of response (38.5% versus 22.8%, p 
0.06), while the gender (p  0.12) was not significantly
associated with objective tumor response. The presence of
EGFR mutation was significantly associated with objective
response to TKIs treatment (p  0.0001). The response rates
of patients with mutant and wild-type EGFR were 71.4%
TABLE 3. Relationships between Molecular Parameters and Clinicopathological Characteristics
Characteristics
Total,
N (%)
EGFR (Tested, 166/166),
N (%)
PIK3CA (Tested, 145/166),
N (%)
KRAS (Tested, 162/166),
N (%)
WT
(n  124)
Mut
(n  42)
WT
(n  139)
Mut
(n  6)
WT
(n  151)
Mut
(n  11)
Gender
Male 91 (54.8) 73 (80.2) 18 (19.8) 78 (97.5) 2 (2.5) 83 (93.2) 6 (6.8)
Female 75 (45.2) 51 (68.0) 24 (32.0) 61 (93.8) 4 (6.2) 68 (93.1) 5 (6.9)
pa 0.10 0.49 0.70
Smoking history
Never smokers 61 (36.7) 41 (67.2) 20 (32.8) 53 (94.6) 3 (3.4) 55 (94.8) 3 (5.2)
Former smokers 47 (28.3) 35 (74.5) 12 (25.5) 38 (97.4) 1 (2.6) 44 (93.6) 3 (6.4)
Current smokers 46 (27.8) 40 (86.9) 6 (13.1) 38 (95.4) 2 (5.0) 40 (88.9) 5 (11.1)
Unknown 12 (7.2) 8 (66.6) 4 (33.4) 10 (100.0) 0 (0.0) 12 (100.0) 0 (0.0)
pa 0.10 0.81 0.40
Histology
ADC/BAC/mixed 126 (75.9) 88 (69.8) 38 (30.2) 102 (94.4) 6 (5.6) 115 (93.4) 8 (6.6)
Other 40 (24.1) 36 (90.0) 4 (10.0) 37 (100.0) 0 (0.0) 36 (92.3) 3 (7.7)
pa 0.01 0.32 0.91
ECOG-PSb
0 109 (65.7) 82 (75.2) 27 (24.8) 92 (97.8) 3 (3.2) 97 (91.5) 9 (8.5)
1 50 (30.1) 39 (78.0) 11 (22.0) 41 (93.2) 3 (6.8) 47 (95.9) 2 (4.1)
2 6 (3.6) 3 (50.0) 3 (50.0) 5 (100.0) 0 (0.0) 6 (100.0) 0 (0.0)
3 1 (0.6) 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
pa 0.15 0.70 0.66
Stageb
III 25 (15.0) 24 (96.0) 1 (4.0) 19 (95.0) 1 (5.0) 25 (100.0) 0 (0.0)
IV 141 (85.0) 100 (70.9) 41 (29.1) 120 (96.0) 5 (4.0) 126 (92.0) 11 (8.0)
pa 0.01 0.69 0.30
a p value calculated using Pearson’s 2 test.
b Data retrieved at start of gefitinib or erlotinib treatment.
ECOG, Eastern Cooperative Oncology Group; PS, performance status; ADC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; WT, wild type; Mut, mutated; EGFR,
epidermal growth factor receptor; PIK3CA, phosphoinositide-3-kinase catalytic alpha; KRAS, Kirsten rat sarcoma viral oncogene homolog.
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(30/42 patients) and 20.1% (25/124 patients), respectively.
The presence of KRAS mutation was significantly associated
with lack of response to TKIs treatment (0.0% mutant versus
35.7% wild type; p  0.03), whereas PIK3CA mutation did
not show a statistical association with response (16.6% mu-
tant versus 35.2% wild type; p  0.61).
TTP and OS According to Clinical and
Molecular Parameters
With a median follow-up of 24.81 months, 147 had
experienced disease progression, and 125 patients had died.
Kaplan-Meier curves of TTP and OS according to molecular
parameters are shown in Figure 2.
A statistically significant shorter OS was observed for
the patients with mutant PIK3CA (log-rank test, p  0.001;
Figure 2E), a trend toward better OS was observed for the
patients with mutant EGFR, but this did not reach statis-
tical significance (log-rank test, p  0.09; Figure 2D),
whereas OS did not differ according to KRAS mutation
(log-rank test, p  0.47; Figure 2F). Median TTP was
significantly shorter in the patients with mutated PIK3CA
and KRAS (log-rank test, p  0.01, Figure 2B, and p 
0.003, Figure 2C, respectively). Longer median TTP was
observed in patients with mutated EGFR (log-rank test,
p  0.0001, Figure 2A).
Multivariate Analyses of Clinical and Molecular
Factors for Response to TKIs and Survival
In a multivariate logistic regression analysis for response
to EGFR-TKIs, performance status 0 and EGFR mutation were
confirmed to be independent predictive favorable factors of
response to TKIs treatment (p  0.01 and p  0.0001, respec-
tively; Table 5). A multivariate Cox regression model for OS
and TTPwas built using the variables that were found significant
at the univariate analysis. PIK3CA mutation (HR: 5.81, 95%
confidence interval [CI]: 2.43–13.91; p  0.0001) and perfor-
mance status (1-2-3 versus 0) (HR: 1.86, 95% CI: 1.25–2.76;
p  0.002) were statistically significant predictors of worse OS
and histology (ADC/BAC/mixed versus other) (HR: 0.49, 95%
CI: 0.32–0.730; p  0.0006) of better OS (Table 5).
PIK3CA mutation (HR: 2.71, 95% CI: 1.23–4.79; p 
0.03), KRAS mutation (HR: 2.43, 95% CI: 1.23–4.79; p 
0.01), and performance status (1–2-3 versus 0) (HR: 2.40,
95% CI: 1.56–3.69; p  0.0001) were statistically significant
predictors of shorter TTP, whereas EGFR mutation (HR:
0.27, 95% CI: 0.14–0.52; p  0.0001) and histology (ADC/
BAC/mixed versus Other) (HR: 0.61, 95% CI: 0.39–0.95;
p  0.03) of longer TTP (data not shown).
DISCUSSION
In this study, we found differences in response and out-
come in patients with advanced NSCLC treated with EGFR-
TABLE 4. Response to EGFR-TKIs, Time to Progression, and Overall Survival According to Clinical and Molecular Parameters
Response to EGFR-TKIs
Time to Progression Overall SurvivalCR  PR,
N (%)
SD  PD,
N (%) p Months HR 95% CI p Months HR 95% CI p
Gender 0.12 0.16 0.36
Male 25 (27.5) 66 (72.5) 4.6 1.30 0.89–1.90 24.9 1.17 0.82–1.68
Female 30 (40.0) 45 (60.0) 6.2 29.1
Smoking history 0.02 0.06 0.47
Never smokers 28 (45.9) 33 (54.0) 10.3 0.68 0.45–1.02 30.6 0.86 0.59–1.27
Former/current smokers 25 (26.7 68 (73.3) 4.6 25
Histology 0.02 0.001 0.002
ADC/BAC/mixed 48 (38.1) 78 (61.9) 6.2 0.52 0.32–0.84 30.6 0.55 0.35–0.86
Other 7 (17.5) 33 (82.5) 2.8 15.8
ECOG-PS 0.06 0.0003 0.0003
0 42 (38.5) 67 (61.5) 6.6 0.44 0.28–0.68 34 0.46 0.30–0.70
1-2-3 13 (22.8) 44 (77.2) 2.8 15.8
EGFR 0.0001 0.0001 0.09
Mutated 30 (71.4) 12 (28.6) — 0.36 0.24–0.55 36.9 0.70 0.47–1.06
Wild type 25 (20.1) 99 (79.8) 3.7 24.8
PIK3CA 0.61 0.01 0.001
Mutated 1 (16.6) 5 (83.4) 2.3 2.9 0.66–12.8 9.9 4.76 0.85–26.57
Wild type 49 (35.2) 90 (64.8) 6.0 30.2
KRAS 0.03 0.003 0.47
Mutated 0 (0) 11 (100.0) 2.7 3.96 5.57–9.99 19.3 1.30 0.63–2.66
Wild type 54 (35.7) 97 (64.3) 5.6 28.6
—, Median PFS not reached.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio; CI, confidence interval; PIK3CA, phosphoinositide-3-kinase catalytic
alpha; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; KRAS, Kirsten rat sarcoma viral oncogene homolog; ADC, adenocarcinoma; BAC, bronchioloalveolar
carcinoma; PS, performance status; ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survival.
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TKIs by EGFR, PIK3CA, and KRAS mutation status. The
frequencies of EGFR (25.3%) and KRAS (6.8%) mutations, the
finding that EGFR and KRAS mutations were mutually exclu-
sive, and the clinical-pathologic characteristics of the patients in
our series are similar to previously published data.13,16 The low
incidence of PIK3CA gene mutation (4.1%) observed in our
study is consistent with previous studies showing that PIK3CA
gene mutation is a rare event in NSCLC, occurring in 1 to 4% of
patients.20
In our study, PIK3CA gene mutation was not mutually
exclusive with EGFR mutation, as it was for KRAS gene,
which is similar to previous reports.27,28 Nevertheless, we
observed PIK3CA mutation in patients with ADC histology,
whereas Yamamoto et al.27 founded PIK3CA copy number
gain, using fluorescence in situ hybridization, more fre-
quently in squamous cell carcinoma (33.1%) than in ADC
(6.2%) or SCLC lines (4.7%).
Although several recent studies have shown that EGFR
mutation predicts favorable response and outcome after treat-
ment with EGFR-TKIs in patients with NSCLC,18,29 KRAS
mutation is known to predict poor outcome after treatment
with EGFR-TKIs in patients with NSCLC.11,30 In our study,
FIGURE 2. Kaplan-Meier curves of
time to progression (TTP) and over-
all survival (OS) on the basis of epi-
dermal growth factor receptor
(EGFR) (A, D), phosphoinositide-3-
kinase catalytic alpha (PIK3CA) (B,
E), and KRAS (C, F) mutational sta-
tus in patients with non-small cell
lung cancer (NSCLC).
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activating PIK3CA and KRAS mutations seem to be predic-
tive of failure of EGFR-TKIs treatment. In fact, all patients
with KRAS mutations and five of six patients with PIK3CA
mutations experienced progressive disease as the best re-
sponse to treatment with EGFR-TKIs. One patient who pre-
sented both EGFR mutation (deletion in exon 19) and
PIK3CA mutation in exon 20 (M1043I) had a short-lasting
response to treatment with erlotinib with a treatment failure
just after 4 months of therapy, which shows that erlotinib
sensitivity conferred by EGFR mutation (deletion in exon 19)
may be incapacitated by the downstream pathway activation
by PIK3CA mutation. The somatic missense mutations found
in our study, which occur predominantly in helical or kinase
domains of catalytic subunit encoded by the PIK3CA gene,
were proposed to increase the kinase activity of PIK3CA
contributing to cellular transformation. The discovery of
hotspot heterozygous mutations strongly argues for the im-
portance of PIK3CA in the carcinogenic process, and the
functional analysis of these mutations has also been per-
formed to confirm this supposition. In fact, Ikenoue et al.31
examining the E542K, E545K, and H1047R hotspots founded
that an increase in PIK3CA kinase activity and cellular
transformation occurred when the aforementioned mutant
PIK3CA sequences were introduced into mouse NIH
3T3cells. Clinically, the presence of PIK3CA mutations has
been linked to both favorable32,33 and unfavorable34,35 patient
prognosis, and it has also been reported that exon 9 mutations
have a less favorable prognosis than exon 20 mutations in
breast cancer.36 The reasons for these conflicting data are not
clear but likely reflect limited sample sizes and difference in
treatment regimens between the various studies. Neverthe-
less, to our knowledge, our study is the first to show that
PIK3CA mutation significantly correlated with worse OS and
shorter TTP of disease in a large group of patients with
NSCLC. A statistically significant difference was found be-
tween the patients with mutation or wild-type PIK3CA (9.9
versus 30.2 months, p  0.001), and this difference remained
statistical significance in multivariate analysis with a relative
risk of 5.81 for reduced OS. This observation raises the
possibility that PIK3CA may serve as a resistant mechanism,
which needs to be clarified in the future.
The response rate to TKIs of 33.1% observed in our
study was higher than previously reported rate in white
population.3–5 This result can partially be attributed to the fact
that the physicians tended to select patients with characteris-
tics known to be predictive for TKIs sensitivity: women,
never smokers, and patients with ADC. Moreover, EGFR
mutation rate of 25% found in our study should be the
consequence of the larger number of never smoker patients
included.
Our findings that EGFR mutation was a significant
predictor of favorable response to EGFR-TKIs (p  0.0001)
and that EGFR mutation was associated with a trend toward
longer OS (p  0.09; Table 4) are in line with the existing
literature.18,29,37 Furthermore, recently, four Asian random-
ized controlled trials compared gefitinib with doublet chemo-
therapy for the treatment of first-line metastatic or locally
advanced NSCLC in clinically selected patients (ADC, never
or former light smokers) or in EGFR-TK-mutated pa-
tients.38–41 In all four trials, gefitinib showed a significant
reduction of hazard ratio (HR) for TTP with a statistical
significant benefit in progression-free survival and a better
outcomes in absolute terms in OS and response rate in
patients harboring the EGFR-TKIs sensitive mutations.
Another interesting finding is the absence of EGFR
mutations in tumors from patients who had stable disease,
three of whom had stable disease for more than 1 year. A
similar observation was previously reported by other au-
thors42 and underscores the importance of defining selection
criteria to identify which patients are most likely to benefit
from EGFR-TKIs.
In conclusion, our findings indicate that PIK3CA mu-
tation is an important predictor of poor outcome in patients
with NSCLC treated with EGFR-TKIs and should be in-
cluded in the panel of markers to be used to predict response
to such therapy. As PIK3CA mutation is a rare event in
advanced NSCLC, these results must be interpreted cau-
tiously and need to be confirmed in large prospective trials,
and its prognostic role should be evaluated further in patients
with NSCLC not exposed to EGFR-TKIs. Moreover, EGFR
mutations are associated with a positive response to TKIs
treatment, as we and others have previously reported. In
patients without EGFR mutations, tumors with KRAS muta-
tions clearly identify patients who do not benefit from EGFR-
TKIs treatment.
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